1. Corporate Officers - S
2. Skvarka Jan

Insider Trading History of Skvarka Jan

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) of Skvarka Jan since 2021. This trader's CIK number is 1838042. At the time of last reporting, Skvarka Jan was the Director of Zentalis Pharmaceuticals, Inc.. (stock ticker symbol ZNTL). Also see all insider trading activities at Zentalis Pharmaceuticals, Inc..

Note that in the past Skvarka Jan also reported insider trading activities as an insider of the following companies:

Yearly summary of insider trading at Zentalis Pharmaceuticals, Inc. (ZNTL) by Skvarka Jan

		Insider Buying		Insider Sales		Option Exercises
Year	Symbol	Shares	Value	Shares	Value	Shares	Value
2025	ZNTL	60,000	$103,440	0	$0	0	$0
2023	ZNTL	0	$0	5,000	$125,239	0	$0

Yearly summary of insider trading at Trillium Therapeutics Inc. (TRIL) by Skvarka Jan

		Insider Buying		Insider Sales		Option Exercises
Year	Symbol	Shares	Value	Shares	Value	Shares	Value
2021	TRIL	0	$0	155,500	$1,577,505	155,500	$58,701

Insider trading activities at 2 companies by Skvarka Jan:

1. Zentalis Pharmaceuticals, Inc. (ZNTL)

2. Trillium Therapeutics Inc. (TRIL)

Table 1. Insider trading of Zentalis Pharmaceuticals, Inc. (ZNTL) by Skvarka Jan

Trade Date	Symbol	Trade Type	Shares	Price ($)	Value ($)
2025-01-31	ZNTL	Buy	60,000	1.72	103,440
2023-09-11	ZNTL	Sale	5,000	25.05	125,239

Table 2. Insider trading of Trillium Therapeutics Inc. (TRIL) by Skvarka Jan

Trade Date	Symbol	Trade Type	Shares	Price ($)	Value ($)
2021-05-11	TRIL	Option Ex	106,698	.38	40,545
2021-05-12	TRIL	Option Ex	23,802	.31	7,473
2021-05-11	TRIL	Sale	106,698	9.20	981,834
2021-05-12	TRIL	Sale	23,802	9.24	219,882
2021-01-13	TRIL	Option Ex	5,419	.42	2,303
2021-01-14	TRIL	Option Ex	19,581	.43	8,380
2021-01-13	TRIL	Sale	5,419	15.04	81,507
2021-01-14	TRIL	Sale	19,581	15.03	294,282

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Skvarka Jan (Director of Zentalis Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.

▪ Real-time Insider Trading

▪ Insider Officer Cluster Trading

▪ Top Officer Buys of the Week

▪ Top Officer Buys of the Month